DSM and Codexis Sign Enzyme Supply Agreement

DSM Pharmaceutical Products and Codexis have signed an enzyme supply agreement, the companies announced. The agreement grants DSM rights to use Codexis' custom biocatalysts and services, and secures supply of Codexis enzymes for commercialization of sustainable enzyme-based pharmaceutical manufacturing routes developed by DSM's InnoSyn route scouting services.

Codexis technology enables development of new efficient manufacturing processes for active pharmaceutical ingredients and intermediates which reduce cost and environmental waste. Codexis technology is used at major pharmaceutical and chemical companies worldwide including Merck, Pfizer and Teva.

The DSM InnoSyn route scouting team integrates cutting edge enzyme technology with the full range of advances in synthetic methods such as homogeneous catalysis, modern organic synthesis and continuous chemistry, using for example micro reactors. The new routes result in increased efficiency of the manufacturing processes while reducing cost and environmental impact.